Participant clinical and demographic characteristics
| Characteristic* | ADHD† | Controls |
|---|---|---|
| Patients (female), n | 25 (6) | 24 (9) |
| Age, yr | 30.08 ± 9.3 | 26.88 ± 6.3 |
| CAARS score, inattention | 19.8 ± 6.5‡ | 6.29 ± 4.8 |
| CAARS score, hyperactivity/impulsivity | 20.32 ± 7.9‡ | 7.58 ± 5.8 |
| WURS-k score | 39.8 ± 11.8‡ | 11.42 ± 7.2 |
| BDI score | 9.44 ± 8.2‡ | 2.04 ± 1.9 |
| Previous substance abuse, n | 9 | — |
| Lifetime comorbidities, n | ||
| Major depression | 5 | — |
| Generalized anxiety disorder < | 5 | — |
| PTSD | < 5 | — |
| Borderline personality disorder | < 5 | — |
| Medication, n | ||
| Methylphenidate | 5 | — |
| Elontril | < 5 | — |
| Sertraline | < 5 | — |
| Triptane | < 5 | — |
| Gestagen | < 5 | — |
| L-thyroxine | < 5 | — |
ADHD = attention-deficit/hyperactivity disorder; BDI = Beck Depression Inventory; CAARS = Conners’ Adult ADHD Rating Scale; PTSD = posttraumatic stress disorder; WURS-k = Wender-Utah-Rating-Scale.
↵* Values are mean ± standard deviation or n.
↵† Values of less than 5 have been rounded to protect participant privacy.
↵‡ Significantly different from controls at p = 0.01.